CN1175822C - Compound electrolyte intra-ocular flushing liquor - Google Patents
Compound electrolyte intra-ocular flushing liquor Download PDFInfo
- Publication number
- CN1175822C CN1175822C CNB021176213A CN02117621A CN1175822C CN 1175822 C CN1175822 C CN 1175822C CN B021176213 A CNB021176213 A CN B021176213A CN 02117621 A CN02117621 A CN 02117621A CN 1175822 C CN1175822 C CN 1175822C
- Authority
- CN
- China
- Prior art keywords
- flushing liquor
- intra
- pulp
- fixed
- ocular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a device in the aspect of machinery, which is structurally characterized in that the device comprises a pulp grinder, a boiled pulp storage tank, a heating slot, a steam generator and an electromagnetic pulp transferring pump, wherein a machine base is fixed to a bottom board by the pulp grinder by utilizing a screw bolt; the boiled pulp storage tank is arranged at the upper left side of the pulp grinder and is fixed to a framework by a connecting sheet; an electrical control box is arranged at the back side of the boiled pulp storage tank, is isolated for heat preservation by adopting polyurethane, and is fixed to a structural framework by a fastening piece; the heating slot is arranged at the left side of the pulp grinder and is fixed to the bottom board after isolated for heat preservation; the steam generator is arranged at the left side of the heating slot, and feet of the generator are fixed to the bottom board by screw bolts after the steam generator is isolated for heat preservation; the electromagnetic pulp transferring pump is arranged at the lower side of the pulp grinder, and the machine base is fixed to the bottom board of the structural framework by a screw bolt; a beverage nozzle is arranged at the upper side of a front panel of the device, and is fixed to the front end of the boiled pulp storage tank via an installing hole by adopting pipeline screw threads.
Description
Affiliated technical field
Intra-ocular flushing liquor---compound electrolyte intra-ocular flushing liquor---is made AK-Rinse in the compound recipe balanced salt, the flushing of inner eye operation open country when being applied to ophthalmologic operation first when the present invention relates to a kind of ophthalmologic operation.
Background technology
Ophthalmologic operation is because its operative site is special, so can not remove operation residue and hemorrhage with conventional methods such as wipings, cataract operation is the main art kind of ophthalmologic operation, the extracapsular cataract extraction operation is after crystal nuclear is given birth to, can leave more cortex among the anterior chamber, must wash away, to reduce after-operation response, and prevent that the back from sending out the formation of cataract, raising along with the ophthalmologic operation level, the cataract operation of immature phase has also generally been carried out, in ophthalmologic operation, also have some operating difficulties higher, require highlyer to perform the operation as vitrectomy, retina shedding is corrected (resetting) operation etc., and flushing liquor used in the operation process is had higher requirement, and it is a lot of that ophthalmologic operation quantity increases, the use of flushing liquor also increases greatly, following process has been experienced in the use of cataract operation anterior chamber flushing liquor substantially: normal saline---Ge Linshi liquid---balanced salt flushing liquor.And the component of balanced salt flushing liquor is minimum to the normal physiological processes influence of human eye near the aqueous humor composition of human eye, and therefore, in ophthalmologic operation, especially intraocular surgery such as cataract generally uses the balanced salt flushing liquor.China all is by hospital preparation chamber self-control balanced salt flushing liquor owing to not having such launch, each tame hospital, because requiring of each tame hospital is inconsistent, causes each tame balanced salt flushing liquor slightly different on prescription, and quality is also irregular to differ.Therefore, development and line balancing salt flushing liquor are the task of top priority of China's ophthalmologic operation medication, are necessary to develop as early as possible listing to satisfy clinical needs.
Summary of the invention
The development of intra-ocular flushing liquor need be satisfied the requirement of the following aspects with exploitation: 1, ocular tissue's composition: the speed of each tissue of ophthalmic during to the chemical constituent of balanced salt flushing liquor, acid-base value, osmotic pressure, temperature and flushing all has higher requirement, otherwise easily ocular tissue is caused harmful effect; 2, chemical constituent: the existing Na that confirmed
+, Cl
-, SO
4 2-, Ca
2+, Mg
2+, glucose is the essential chemical constituent of flushing liquor, if the composition of flushing liquor is improper, the corneal endotheliocyte produces illeffects, corneal edema can occur; 3, acid-base value: the pH value of human eye tear, preceding aqueous humor is generally 7.2-7.4, and the pH value of flushing liquor then should be controlled at 6.9-7.5; Flushing liquor is to the broad that requires of osmotic pressure, the osmotic pressure that is equivalent to 0.6-1.4% sodium chloride all can, can not produce harmful effect to human eye; For satisfying above requirement, we have developed compound electrolyte intra-ocular flushing liquor, and are domestic clinical during to ophthalmologic operation to satisfy, the needs that ophthalmic perfusion and flushing liquor are growing.It is slightly different on prescription not only to have solved the balanced salt flushing liquor that each hospital prepares voluntarily, the quality also irregular problem that differs, and also the component of compound electrolyte intra-ocular flushing liquor is minimum to the normal physiological processes influence of human eye near the aqueous humor composition of human eye.
Technical scheme of the present invention is: a kind of compound electrolyte intra-ocular flushing liquor, it is characterized in that containing glucose 1.5-7.5g in per 1000 milliliters of flushing liquors, tartaric acid 0.55-2.75g, sodium chloride 6.6-33.0g, potassium chloride 0.36-1.8g, calcium chloride 0.18-0.9g, magnesium sulfate 0.3-1.5g, sodium bicarbonate 2.1-10.5g.
The preparation method of the medicine bottle of compound electrolyte intra-ocular flushing liquor is characterized in that getting glucose, tartaric acid, sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate and joins successively in an amount of water for injection and dissolve; The needle-use activated carbon desuperheating source of adding 0.5% is placed more than 12 hours; Filter moisturizing; Packing, every bottle feeds carbon dioxide to the acid-base value of medicinal liquid and reaches pH value 7.2-7.4, sealing immediately; In 115 ℃ of following pressure sterilizings 30 minutes, check packing.
Compound electrolyte intra-ocular flushing liquor is applied to application in the medicine in the ophthalmologic operation in preparation.
With reference to the aqueous humor composition of human eye, the balanced salt flushing liquor prescription of the external listing of reference is also considered domestic raw material condition, develops compound electrolyte intra-ocular flushing liquor.Its concrete feature is as follows:
Compound electrolyte intra-ocular flushing liquor of the present invention is three class compound preparations, each material composition and in following ratio form be applied to ophthalmologic operation the time in the preparation of eye flushing: contain glucose 1.5g in wherein per 1000 milliliters of flushing liquors, tartaric acid 0.55g, sodium chloride 6.6g, potassium chloride 0.36g, calcium chloride 0.18g, magnesium sulfate 0.3g, sodium bicarbonate 2.1g, preparation technology as shown in Figure 1 is: get glucose, tartaric acid, sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate and join successively in an amount of water for injection and dissolve; The needle-use activated carbon desuperheating source of adding 0.5% is placed more than 12 hours; Filter, moisturizing is to full dose; Packing, every bottle fed carbon dioxide about 1 minute, immediately sealing; In 115 ℃ of following pressure sterilizings 30 minutes, check, packing, promptly.Among the above-mentioned preparation technology, its core technology is: (1). acid-base value is regulated: the method for mentioning in the documents and materials all is to regulate acid-base value with mineral acid, alkali, make the final acid-base value of product reach proper level, because the complexity of prescription, available soda acid is very limited, control method also is difficult to select, and we select for use carbon dioxide to regulate acid-base value, and the good results are evident; In general industrial is produced, the use of the chemicals of solid, liquid, can be than being easier to solve quantitative problem, but in the application of gas chemicals, it is quite crucial that quantitative problem just becomes, carbon dioxide dissolubility in water is limited, and vary with temperature and change, it is also less to regulate the used amount of acid-base value, we regulate ventilation by regulating duration of ventilation, and be aided with technology controlling and process such as temperature, filtration, fill, the acid-base value of medicinal liquid is reached about pH7.3, near the acid-base value of people's aqueous humor.(2). medicinal liquid clarity is regulated: the subject matter that influences medicinal liquid clarity is that calcium, magnesium salt are precipitated out from medicinal liquid; In the production process of product, along with the medicinal liquid acid-base value is regulated the solution of problem, this problem is also known about the way of determining: the medicine bottle behind the feeding carbon dioxide, at suitable temperature (40-45 ℃) and pressure (0.05MPa) lower seal, pressure sterilizing; Sterilization finishes, and temperature is reduced to room temperature, and system recovery does not have precipitation and occurs to primary poised state, and the clarity of medicinal liquid is guaranteed.(3). the glucose heat stability: the glucose in this product prescription is as nutritional labeling, its concentration be lower than 5% and the high temperature sterilize process in variation and structural transformation problem, because oxygen decomposes and optical isomerism causes, we feed the carbon dioxide deoxidation and solve discoloration problem, simultaneously, a kind of raw material in the prescription that we adopted can stop the optical isomerism problem of glucose, under present use amount, the d-isomer content of glucose by sterilization basic guarantee constant, the requirement that our product glucose content can be reached quality standards all the time.(4). with the product suitability, the relevant packaging Problems of safety: in order to guarantee medicinal liquid stable and safety in use, initiated gas at home---liquid separate type packing, filled up domestic blank.One, the product suitability: in present ophthalmologic operation, drug combination is very general, as in operation process, share antibiotic, share antioxidant etc., the overall process that is accompanied by operation is used in uniting of these medicines, we leave feeding opening and visible marking on the bottle cap (plug) of compound electrolyte intra-ocular flushing liquor, so that doctor easy to operate when needing drug combination.Two, Product Safety: in operation process, aseptic requirement to product is very high, generally speaking, all require product and environment aseptic, therefore, we have added the glass tubing of an air inlet on bottle stopper, air (through filtering) enters the bottle bottom from glass tubing, the just liquid level of medicinal liquid that can contact, in case antibacterial enters medicine bottle, it can not mix with medicinal liquid and only rest on liquid level position (common air inlet method, air reaches the bottle bottom by the bottleneck remainder medicinal liquid in bottle that stands upside down), only pollutes the liquid level part of medicinal liquid.If medicinal liquid is under situation about not exclusively using up, operation is comparatively safe.
Good effect of the present invention: (1). use compound electrolyte intra-ocular flushing liquor to replace previously used normal saline and Ge Linshi liquid, solve the balanced salt flushing liquor and prepare voluntarily, prescription and all discrepant problem of quality by each tame hospital preparation chamber.(2). our enterprise is the ophthalmic remedy manufacturer of domestic specialty, is devoted to production, development, the exploitation of ophthalmic remedy over more than 30 year always, actively participates in work for the public good, and ophthalmic remedy accounts for more than 90% of the gross output value.
Embodiment
Prescription 1:
Glucose 1.50g
Tartaric acid 0.55g
Sodium chloride 6.60g
Potassium chloride 0.36g
Calcium chloride 0.18g
Magnesium sulfate 0.30g
Sodium bicarbonate 2.10g
Water for injection is to 1000ml
Preparation technology
1. getting glucose, tartaric acid, sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate joins successively in an amount of water for injection and dissolves;
2. add 0.5% injection-use activated carbon desuperheating source, place more than 12 hours;
3. filter, moisturizing is to full dose;
4. packing, every bottle fed carbon dioxide about 1 minute, immediately sealing;
5. in 115 ℃ of following pressure sterilizings 30 minutes, packing, promptly.
Description of the process: feed carbon dioxide and be that sodium bicarbonate resolves into sodium carbonate when preventing to sterilize; Regulate medicinal liquid clarity and solve the flushing liquor discoloration problem.
Prescription 2:
Glucose 0-7.5g
Tartaric acid 0-2.75g
Sodium chloride 0-33.0g
Potassium chloride 0-1.8g
Calcium chloride 0-0.9g
Magnesium sulfate 0-1.5g
Sodium bicarbonate 0-10.5g
Water for injection is to 1000ml
Preparation technology
1. getting glucose, tartaric acid, sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate joins successively in an amount of water for injection and dissolves;
2. add 0.5% injection-use activated carbon desuperheating source, place more than 12 hours.
3. filter, moisturizing is to full dose;
4. packing, every bottle fed carbon dioxide about 1 minute, immediately sealing;
5. in 115 ℃ of following pressure sterilizings 30 minutes, packing, promptly.
Creativeness of the present invention realizes by clinical, toxicology and pharmacology data, provides in the lump during examination as to substances.
Accompanying drawing 1 is a compound electrolyte intra-ocular flushing liquor preparation technology flow chart.
Claims (4)
1. a compound electrolyte intra-ocular flushing liquor is characterized in that containing glucose 1.5-7.5g, tartaric acid 0.55-2.75g in per 1000 milliliters of flushing liquors, sodium chloride 6.6-33.0g, potassium chloride 0.36-1.8g, calcium chloride 0.18-0.9g, magnesium sulfate 0.3-1.5g, sodium bicarbonate 2.1-10.5g.
2. according to the compound electrolyte intra-ocular flushing liquor of claim 1, it is characterized in that containing glucose 1.50g in per 1000 milliliters of flushing liquors, tartaric acid 0.55g, sodium chloride 6.60g, potassium chloride 0.36g, calcium chloride 0.18g, magnesium sulfate 0.30g, sodium bicarbonate 2.10g.
3. preparation method that comprises the medicine bottle of the described compound electrolyte intra-ocular flushing liquor of claim 1 is characterized in that getting glucose, tartaric acid, sodium chloride, potassium chloride, calcium chloride, magnesium sulfate, sodium bicarbonate and joins successively in an amount of water for injection and dissolve; The needle-use activated carbon desuperheating source of adding 0.5% is placed more than 12 hours; Filter moisturizing; Packing, every bottle feeds carbon dioxide to the acid-base value of medicinal liquid and reaches pH value 7.2-7.4, sealing immediately; In 115 ℃ of following pressure sterilizings 30 minutes, check packing.
4. the described compound electrolyte intra-ocular flushing liquor of claim 1 is applied to application in the medicine in the ophthalmologic operation in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021176213A CN1175822C (en) | 2002-05-10 | 2002-05-10 | Compound electrolyte intra-ocular flushing liquor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021176213A CN1175822C (en) | 2002-05-10 | 2002-05-10 | Compound electrolyte intra-ocular flushing liquor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1456171A CN1456171A (en) | 2003-11-19 |
| CN1175822C true CN1175822C (en) | 2004-11-17 |
Family
ID=29410326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021176213A Expired - Lifetime CN1175822C (en) | 2002-05-10 | 2002-05-10 | Compound electrolyte intra-ocular flushing liquor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1175822C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101721423B (en) * | 2008-10-21 | 2012-05-23 | 曾因明 | Bicarbonate physiological balanced solution and preparation method thereof |
| CN101721424B (en) * | 2008-10-21 | 2012-07-25 | 曾因明 | Bicarbonate physiological balanced solution and preparation method thereof |
| CN106135197B (en) * | 2016-07-04 | 2018-03-02 | 拜欧迪赛尔（北京）生物科技有限公司 | A kind of cornea mid-term preservation liquid of serum-free composition |
| CN107050086A (en) * | 2017-02-07 | 2017-08-18 | 商丘市第人民医院 | A kind of ophthalmology cleaning agent and preparation method thereof |
-
2002
- 2002-05-10 CN CNB021176213A patent/CN1175822C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1456171A (en) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109364019A (en) | A kind of eye-drops preparations and preparation method thereof for preventing and treating cataract | |
| CN106822175A (en) | A kind of sodium acid carbonate ringer's injection and preparation method thereof | |
| CN1175822C (en) | Compound electrolyte intra-ocular flushing liquor | |
| CN104055766A (en) | Pharmaceutical composition of compound amino acid injection 18AA and application thereof | |
| EP0115911B2 (en) | Peritoneal dialysis solutions and preparation thereof | |
| CN102579329A (en) | Milrinone lactate injection and preparation method thereof | |
| CN107823149A (en) | A kind of injection Angiomax and preparation method thereof | |
| CN102441001A (en) | Compound allantoin vitamin B6-E and ammoniation ethyl sulfate eye drops and preparation method thereof | |
| CN105287369A (en) | Production method for preventing turbidity of plastic-bottle sodium chloride injection | |
| CN108403691A (en) | A kind of new application of Edaravone | |
| CN104721223B (en) | A kind of injection pharmaceutical composition of compound electrolyte and preparation method thereof | |
| CN101664385B (en) | Ibutilide fumarate injection and preparation method thereof | |
| CN103340853A (en) | Compound 18-amino acid injection containing little amount of antioxidant and preparation method thereof | |
| CN103371967A (en) | Furosemide injection and preparation process thereof | |
| CN1954855B (en) | Eye preparation containing sodium hyaluronate for treating fundus macular degeneration and its preparation method | |
| CN106692184A (en) | Compound sodium chloride injection containing sodium lactate | |
| CN1316975C (en) | Puerarin prepn for eye and its prepn process | |
| CN115227647B (en) | Sodium cromoglicate eye drops without preservative and preparation method thereof | |
| CN1245981C (en) | Liquid preparation made from pazufloxacin leucinocaine fed through eye in application of curing ophthalmic diseases and producing method | |
| CN1698595B (en) | Tiopronin injection and preparation method thereof | |
| CN103932995B (en) | A kind of lentinan agent and preparation method thereof | |
| AU721623B2 (en) | Improved intraocular irrigating solution containing a polyamine antagonist | |
| CN1887290B (en) | Lincomycin hydrochloride composition and its prepn | |
| CN106344502A (en) | Pharmaceutical composition for injection capable of improving stability of leech drug injection preparation | |
| CN105982915A (en) | Preparation method of potassium chloride injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHENYANG XINGQI MEDICINE CO., LTD. Free format text: FORMER OWNER: LIU JIDONG Effective date: 20111013 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20111013 Address after: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee after: Shenyang Sinqi Pharmaceutical Co., Ltd. Address before: 110027, Liaoning, Shenyang economic and Technological Development Zone, No. three, 12, No. 4, Shenyang Xing Qi Pharmaceutical Co., Ltd. Patentee before: Liu Jidong |
|
| C56 | Change in the name or address of the patentee |
Owner name: SHENYANG SINQI EYE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SHENYANG XINGQI MEDICINE CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: 110024, 4, 12, three street, Shenyang economic and Technological Development Zone Patentee after: Shenyang Sinqi Pharmaceutical Co., Ltd. Address before: 110027 No. 12, 4, three street, Shenyang economic and Technological Development Zone, Liaoning, China Patentee before: Shenyang Sinqi Pharmaceutical Co., Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20041117 |
|
| CX01 | Expiry of patent term |